Haemoglobin a1c even within non-diabetic level is a predictor of cardiovascular disease in a general japanese population: The hisayama study

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Ikeda, Fumie ^a   Doi, Yasufumi ^a   Ninomiya, Toshiharu ^a   Hirakawa, Yoichiro ^a   Mukai, Naoko ^a   Hata, Jun ^a   Shikata, Kentaro ^a   Yoshida, Daigo ^a   Matsumoto, Takayuki ^a   Kitazono, Takanari ^a   Kiyohara, Yutaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Cardiovascular disease; Epidemiology; Haemoglobin A1c; Prospective cohort study; Risk factor

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; JAPAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 84887127447     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-164     Document Type: Article

References (40)

1. Burchfiel CM, Curb JD, Rodriguez BL, Abbott RD, Chiu D, Yano K. Glucose intolerance and 22-year stroke incidence. The Honolulu heart program. Stroke 1994, 25:951-957. 10.1161/01.STR.25.5.951, 8165689.
2. Meigs JB, Nathan DM, D'Agostino RB, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham offspring study. Diabetes Care 2002, 25:1845-1850. 10.2337/diacare.25.10.1845, 12351489.
3. Doi Y, Ninomiya T, Hata J, Fukuhara M, Yonemoto K, Iwase M, Iida M, Kiyohara Y. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama Study. Stroke 2010, 41:203-209. 10.1161/STROKEAHA.109.564708, 19940278.
4. The American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33:S62-S69. 2797383, 20042775, The American Diabetes Association.
5. Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007, 167:1545-1551. 10.1001/archinte.167.14.1545, 17646610.
6. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004, 141:413-420. 10.7326/0003-4819-141-6-200409210-00006, 15381514.
7. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 2005, 165:1910-1916. 10.1001/archinte.165.16.1910, 16157837.
8. Selvin E, Coresh J, Shahar E, Zhang L, Steffes M, Sharrett AR. Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the atherosclerosis risk in communities (ARIC) study. Lancet Neurol 2005, 4:821-826. 10.1016/S1474-4422(05)70227-1, 16297840.
9. Gerstein HC, Pogue J, Mann JF, Lonn E, Dagenais GR, McQueen M, Yusuf S. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005, 48:1749-1755. 10.1007/s00125-005-1858-4, 16059716.
10. Myint PK, Sinha S, Wareham NJ, Bingham SA, Luben RN, Welch AA, Khaw KT. Glycated hemoglobin and risk of stroke in people without known diabetes in the European Prospective Investigation into Cancer (EPIC)-Norfolk prospective population study: a threshold relationship?. Stroke 2007, 38:271-275. 10.1161/01.STR.0000254549.75763.5f, 17204684.
11. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010, 362:800-811. 10.1056/NEJMoa0908359, 2872990, 20200384.
12. Sunaga K, Miura K, Naruse Y, Sakurai M, Morikawa Y, Kurosawa Y, Nakagawa H. Glycated hemoglobin and risk of stroke, ischemic and hemorrhagic, in Japanese men and women. Cerebrovasc Dis 2008, 26:310-316. 10.1159/000149579, 18667812.
13. Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Okayama A, Okamura T. New diagnosis criteria for diabetes with hemoglobin A1c and risks of macro-vascular complications in an urban Japanese cohort: the Suita study. Diabetes Res Clin Pract 2010, 88:e20-e23. 10.1016/j.diabres.2010.01.019, 20149470.
14. Nakanishi S, Yamada M, Hattori N, Suzuki G. Relationship between HbA1c and mortality in a Japanese population. Diabetologia 2005, 48:230-234. 10.1007/s00125-004-1643-9, 15650819.
15. Simmons RK, Sharp S, Boekholdt SM, Sargeant LA, Khaw KT, Wareham NJ, Griffin SJ. Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events?. Arch Intern Med 2008, 168:1209-1216. 10.1001/archinte.168.11.1209, 18541829.
16. Ohmura T, Ueda K, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Nomiyama K, Ohmori S, Yoshitake T, Shinkawa A, Hasuo Y, Fujishima M. Prevalence of type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: the Hisayama Study. Diabetologia 1993, 36:1198-1203. 10.1007/BF00401066, 8270136.
17. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Japan Diab Soc 2010, 53:450-467. The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus.
18. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845. 10.2307/2531595, 3203132.
19. Pencina MJ, D'Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21. 10.1002/sim.4085, 3341973, 21204120.
20. Lauritzen T, Sandbaek A, Carlsen AH, Borch-Johnsen K. All-cause mortality and pharmacological treatment intensity following a high risk screening program for diabetes. A 6.6 year follow-up of the ADDITION study, Denmark. Prim Care Diabetes 2012, 6:193-200. 10.1016/j.pcd.2012.04.005, 22595031.
21. Liu Y, Yang YM, Zhu J, Tan HQ, Liang Y, Li JD. Prognostic significance of hemoglobin A1c level in patients hospitalized with coronary artery disease. A systematic review and meta-analysis. Cardiovasc Diabetol 2011, 10:98. 10.1186/1475-2840-10-98, 3225330, 22074110.
22. Kerr D, Partridge H, Knott J, Thomas PW. HbA1c 3 months after diagnosis predicts premature mortality in patients with new onset type 2 diabetes. Diabet Med 2011, 28:1520-1524. 10.1111/j.1464-5491.2011.03443.x, 21913968.
23. Kassaian SE, Goodarzynejad H, Boroumand MA, Salarifar M, Masoudkabir F, Mohajeri-Tehrani MR, Pourhoseini H, Sadeghian S, Ramezanpour N, Alidoosti M, Hakki E, Saadat S, Nematipour E. Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting. Cardiovasc Diabetol 2012, 11:82. 10.1186/1475-2840-11-82, 3444922, 22805289.
24. Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, Zhou Y, Ma C. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2011, 10:19. 10.1186/1475-2840-10-19, 3056765, 21349201.
25. Neuhold S, Resl M, Huelsmann M, Strunk G, Adlbrecht C, Rath C, Prager R, Luger A, Clodi M, Pacher R. Repeat measurements of glycated haemoglobin A(1c) and N-terminal pro-B-type natriuretic peptide: divergent behaviour in diabetes mellitus. Eur J Clin Invest 2011, 41:1292-1298. 10.1111/j.1365-2362.2011.02539.x, 21615391.
26. van 't Riet E, Rijkelijkhuizen JM, Alssema M, Nijpels G, Stehouwer CD, Heine RJ, Dekker JM. HbA1c is an independent predictor of non-fatal cardiovascular disease in a Caucasian population without diabetes: a 10-year follow-up of the Hoorn study. Eur J Prev Cardiol 2012, 19:23-31. 10.1097/HJR.0b013e32833b0932, 20517157.
27. Ikeda N, Iijima R, Hara H, Moroi M, Nakamura M, Sugi K. Glycated hemoglobin is associated with the complexity of coronary artery disease, even in non-diabetic adults. J Atheroscler Thromb 2012, 19:1066-1072. 10.5551/jat.13722, 22878698.
28. Brewer N, Wright CS, Travier N, Cunningham CW, Hornell J, Pearce N, Jeffreys M. A New Zealand linkage study examining the associations between A1C concentration and mortality. Diabetes Care 2008, 31:1144-1149. 10.2337/dc07-2374, 18299440.
29. Collins C. Pathophysiology and classification of stroke. Nurs Stand 2007, 21:35-39.
30. Turk Z, Mesić R, Benko B. Comparison of advanced glycation endproducts on haemoglobin (Hb-AGE) and haemoglobin A1c for the assessment of diabetic control. Clin Chim Acta 1998, 277:159-170. 10.1016/S0009-8981(98)00128-4, 9853699.
31. Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 1992, 258:651-653. 10.1126/science.1411574, 1411574.
32. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820. 10.1038/414813a, 11742414.
33. Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011, 46:217-224. 10.1016/j.exger.2010.11.007, 21111800.
34. Raposeiras-Roubín S, Rodiño-Janeiro BK, Paradela-Dobarro B, Grigorian-Shamagian L, García-Acuña JM, Aguiar-Souto P, Jacquet-Hervet M, Reino-Maceiras MV, Alvarez E, González-Juanatey JR. Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report. Cardiovasc Diabetol 2012, 11:102. 10.1186/1475-2840-11-102, 3489693, 22909322.
35. Fukushima Y, Daida H, Morimoto T, Kasai T, Miyauchi K, Yamagishi S, Takeuchi M, Hiro T, Kimura T, Nakagawa Y, Yamagishi M, Ozaki Y, Matsuzaki M, JAPAN-ACS Investigators Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovasc Diabetol 2013, 12:5. 10.1186/1475-2840-12-5, 3571912, 23289728, JAPAN-ACS Investigators.
36. Barr EL, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian diabetes, obesity, and lifestyle (AusDiab) study. Diabetologia 2009, 52:415-424. 10.1007/s00125-008-1246-y, 19130039.
37. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjörnsdóttir S, Eliasson B. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med 2010, 268:471-482. 10.1111/j.1365-2796.2010.02265.x, 20804517.
38. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjörnsdóttir S, Eliasson B. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Care 2010, 33:1640-1646. 10.2337/dc10-0398, 2890374, 20424222.
39. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, Zagar T, Poole CD. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010, 375:481-489. 10.1016/S0140-6736(09)61969-3, 20110121.
40. Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S, Fulcher G, de Galan BE, Harrap S, Hamet P, Heller S, MacMahon S, Marre M, Poulter N, Travert F, Patel A, Neal B, Woodward M, for the Advance Collaborative Group Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012, 55:636-643. 10.1007/s00125-011-2404-1, 22186981, for the Advance Collaborative Group.